XORTX Therapeutics Inc. (TSXV:XRTX)
Canada
· Delayed Price · Currency is CAD 0.600
0.00 (0.00%)
At close: Mar 6, 2026
XORTX Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Cash & Equivalents | 0.86 | 2.47 | 3.45 | 10.43 | 14.87 | Upgrade
|
| Cash & Short-Term Investments | 0.86 | 2.47 | 3.45 | 10.43 | 14.87 | Upgrade
|
| Cash Growth | -65.05% | -28.25% | -66.96% | -29.83% | 10962.65% | Upgrade
|
| Other Receivables | 0.08 | 0.02 | 0.06 | 0.08 | 0.04 | Upgrade
|
| Receivables | 0.08 | 0.02 | 0.06 | 0.08 | 0.04 | Upgrade
|
| Prepaid Expenses | 0.02 | 0.18 | 0.24 | 0.38 | 0.44 | Upgrade
|
| Other Current Assets | 0.29 | 0 | 0.32 | - | 0.56 | Upgrade
|
| Total Current Assets | 1.26 | 2.68 | 4.07 | 10.9 | 15.91 | Upgrade
|
| Property, Plant & Equipment | 0.04 | 0.03 | 0.02 | 0.09 | - | Upgrade
|
| Other Intangible Assets | 0.19 | 0.18 | 0.18 | 0.2 | 0.2 | Upgrade
|
| Other Long-Term Assets | 1.2 | 1.2 | 1.2 | 1.19 | 1.27 | Upgrade
|
| Total Assets | 2.68 | 4.09 | 5.47 | 12.37 | 17.38 | Upgrade
|
| Accounts Payable | 0.55 | 0.08 | 0.2 | 1.29 | 0.32 | Upgrade
|
| Accrued Expenses | - | 0.06 | 0.09 | 0.15 | 0.23 | Upgrade
|
| Current Portion of Leases | 0.04 | 0.04 | 0.01 | 0.07 | - | Upgrade
|
| Other Current Liabilities | 0.01 | 0.57 | 0.53 | - | - | Upgrade
|
| Total Current Liabilities | 0.6 | 0.76 | 0.83 | 1.51 | 0.55 | Upgrade
|
| Long-Term Leases | - | - | - | 0.01 | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 3.85 | 3.63 | Upgrade
|
| Total Liabilities | 0.6 | 0.76 | 0.83 | 5.38 | 4.18 | Upgrade
|
| Common Stock | 20.18 | 18.49 | 17.06 | 16.52 | 16.09 | Upgrade
|
| Retained Earnings | -23.82 | -21.17 | -17.85 | -15.7 | -7.98 | Upgrade
|
| Comprehensive Income & Other | 5.73 | 6.01 | 5.44 | 6.17 | 5.09 | Upgrade
|
| Shareholders' Equity | 2.08 | 3.34 | 4.64 | 7 | 13.2 | Upgrade
|
| Total Liabilities & Equity | 2.68 | 4.09 | 5.47 | 12.37 | 17.38 | Upgrade
|
| Total Debt | 0.04 | 0.04 | 0.01 | 0.08 | - | Upgrade
|
| Net Cash (Debt) | 0.83 | 2.43 | 3.44 | 10.36 | 14.87 | Upgrade
|
| Net Cash Growth | -66.03% | -29.14% | -66.82% | -30.35% | 10962.65% | Upgrade
|
| Net Cash Per Share | 0.17 | 0.85 | 1.73 | 7.00 | 13.59 | Upgrade
|
| Filing Date Shares Outstanding | 6.54 | 3.79 | 2.9 | 2 | 1.44 | Upgrade
|
| Total Common Shares Outstanding | 6.54 | 3.48 | 2 | 1.67 | 1.44 | Upgrade
|
| Working Capital | 0.66 | 1.92 | 3.24 | 9.38 | 15.36 | Upgrade
|
| Book Value Per Share | 0.32 | 0.96 | 2.32 | 4.19 | 9.15 | Upgrade
|
| Tangible Book Value | 1.9 | 3.15 | 4.47 | 6.8 | 13 | Upgrade
|
| Tangible Book Value Per Share | 0.29 | 0.91 | 2.23 | 4.07 | 9.01 | Upgrade
|
| Machinery | - | 0.02 | 0.02 | 0.02 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.